Anti-atherosclerotic effects of pravastatin in brachiocephalic artery in comparison with en face aorta and aortic roots in ApoE/LDLR-/- mice

Pharmacol Rep. 2017 Feb;69(1):112-118. doi: 10.1016/j.pharep.2016.09.014. Epub 2016 Sep 17.

Abstract

Background: Cholesterol-dependent and independent mechanisms were proposed to explain anti-atherosclerotic action of statins in humans. However, their effects in murine models of atherosclerosis have not been consistently demonstrated. Here, we studied the effects of pravastatin on atherosclerosis in ApoE/LDLR-/- mice fed a control and atherogenic diet.

Methods: ApoE/LDLR-/- mice were fed a control (CHOW) or an atherogenic (Low Carbohydrate High Protein, LCHP) diet. Two doses of pravastatin (40mg/kg and 100mg/kg) were used. The anti-atherosclerotic effects of pravastatin in en face aorta, cross-sections of aortic roots and brachiocephalic artery (BCA) were analysed. The lipid profile was determined. Fourier Transform Infrared Spectroscopy followed by Fuzzy C-Means (FCM) clustering was used for the quantitative assessment of plaque composition.

Results: Treatment with pravastatin (100mg/kg) decreased total and LDL cholesterol only in the LCHP group, but displayed a pronounced anti-atherosclerotic effect in BCA and abdominal aorta. The anti-atherosclerotic effect of pravastatin (100mg/kg) in BCA was associated with significant alterations of the chemical plaque composition, including a fall in cholesterol and cholesterol esters contents independently on total cholesterol and LDL concentration in plasma.

Conclusions: Pravastatin at high (100mg/kg), but not low dose displayed a pronounced anti-atherosclerotic effect in ApoE/LDLR-/- mice fed a CHOW or LCHP diet that was remarkable in BCA, visible in en face aorta, whereas it was not observed in aortic roots, suggesting that previous inconsistencies might have been due to the various sites of atherosclerotic plaque analysis.

Keywords: ApoE/LDLR(−/−) mice; Atherosclerosis; Pravastatin.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Anticholesteremic Agents / pharmacology
  • Anticholesteremic Agents / therapeutic use
  • Aorta / drug effects*
  • Aorta / metabolism
  • Aorta / pathology
  • Apolipoproteins E / deficiency*
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / metabolism
  • Atherosclerosis / pathology
  • Brachiocephalic Trunk / drug effects*
  • Brachiocephalic Trunk / metabolism
  • Brachiocephalic Trunk / pathology
  • Female
  • Mice
  • Mice, Knockout
  • Pravastatin / pharmacology
  • Pravastatin / therapeutic use*
  • Receptors, LDL / deficiency*
  • Treatment Outcome

Substances

  • Anticholesteremic Agents
  • Apolipoproteins E
  • Receptors, LDL
  • Pravastatin